Sei Investments Co. Has $16.84 Million Stock Holdings in Twist Bioscience Corporation $TWST

Sei Investments Co. increased its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 31.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 354,420 shares of the company’s stock after purchasing an additional 84,321 shares during the quarter. Sei Investments Co.’s holdings in Twist Bioscience were worth $16,842,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TWST. William Blair Investment Management LLC lifted its stake in Twist Bioscience by 43.7% in the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares in the last quarter. EdgePoint Investment Group Inc. grew its stake in Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after purchasing an additional 1,080,722 shares during the period. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after purchasing an additional 832,687 shares during the period. Finally, Balyasny Asset Management L.P. lifted its position in shares of Twist Bioscience by 934.0% in the second quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock worth $23,113,000 after purchasing an additional 567,481 shares in the last quarter.

Twist Bioscience Trading Down 3.5%

NASDAQ:TWST opened at $85.47 on Thursday. The stock’s 50 day moving average price is $83.72 and its 200 day moving average price is $61.36. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $105.47. The company has a market capitalization of $5.32 billion, a P/E ratio of -64.26 and a beta of 2.11. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. Twist Bioscience’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.66) EPS. On average, research analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird raised their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a research note on Thursday, July 16th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research report on Monday, July 6th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Finally, Piper Sandler began coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $90.30.

Insider Activity at Twist Bioscience

In other news, Director Jan Johannessen sold 12,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares in the company, valued at approximately $996,354.48. This trade represents a 40.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 50,211 shares of company stock worth $4,199,331 over the last quarter. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.